Greenwich Lifesciences

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly 3,000% in a single day in December after a Phase 2b trial suggested the therapy can reduce breast cancer recurrence rates down to zero.

Exclusive: Greenwich LifeSciences CEO Calls Stock's Meteoric Rise 'Very Emotional'

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting

Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour - Interview will air on Thursday, March 11, 2021 at 12:30 pm EST

Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour

Why Greenwich LifeSciences Stock Skyrocketed Today

GLSI stock is skyrocketing again on Monday after the company appointed Dr. Jaye Thompson to run its Phase 3 clinical trials. The post GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today appeared first on InvestorPlace.

GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today

The stock price of Greenwich Lifesciences Inc (NASDAQ: GLSI) increased by over 130% during intraday trading. This is why it happened.

GLSI Stock Price Increased Over 130% Intraday: Why It Happened

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer

Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and Bio-Europe Spring Conferences

Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference

Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Exercise and Closing of Underwriter's Over-Allotment Option

Greenwich LifeSciences Announces Exercise and Closing of Underwriter's Over-Allotment Option

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report

Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences

Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week

Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences' LD Micro Presentation Replay Now Available

Greenwich LifeSciences' LD Micro Presentation Replay Now Available

Immutep Ltd

SELLAS Life Sciences Group

Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for effective treatments.

Shares of Startup Biotechs Soar on Cancer Study Results

A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.

This Was the Top-Performing IPO in 2020

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28

Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock

Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock

The company announced the pricing of a public offering of common stock.

Why Greenwich LifeSciences Stock Is Plunging Today

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock

Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock

New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/greenwich-lifesciences-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates

Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates

The stock price of Greenwich Lifesciences Inc (NASDAQ: GLSI) has increased by 1,120% over the past month. This is why it happened.

GLSI Stock Price Increases Over 1,120% This Past Month: Why It Happened

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer

Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer

Tenet Healthcare

Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metastatic breast cancer. Immutep is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases.

News for Greenwich Lifesciences Stock (GLSI)